From GlobeNewswire: 2025-04-22 20:34:00

Recursion, a TechBio company, will present preliminary data at the 2025 Digestive Disease Week meeting for its Phase 1b/2 clinical trial on REC-4881 for familial adenomatous polyposis (FAP). The drug has shown promise in reducing polyp burden in patients. FAP affects about 50,000 people in the US and Europe, with no FDA-approved treatments available. REC-4881 has Fast Track and Orphan Drug designation. The late-breaking abstract showed positive results, with 84.6% of patients experiencing at least one treatment-related adverse event. The data will be presented in May at DDW. For more information, visit www.ddw.org.



Read more at GlobeNewswire: Recursion to Present Preliminary Clinical Data from the